Luteolin
别名: Luteoline, Luteolol, Digitoflavone 中文名称：木犀草素，四羟黄酮
Luteolin (Luteoline, Luteolol, Digitoflavone)是一种非选择性的PDE抑制剂，作用于PDE1-5，Ki分别为15.0 μM， 6.4 μM， 13.9 μM， 11.1 μM和9.5 μM。
Luteolin Chemical Structure
CAS: 491-70-3
产品质控
批次：
纯度：
99.18%
99.18
Luteolin相关产品
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| human THP1 cells | Function assay | 20 μM | 1 h | Downregulation of TPA-induced NOX2 mRNA expression in human THP1 cells at 20 uM incubated for 1 hr prior to TPA challenge measured after 24 hrs by RT-PCR analysis | 23786520 |
| MDA-MB-231 cells | Function assay | 5 μM | 16 h | Inhibition of PMA-stimulated NF-kappaB signaling (unknown origin) expressed in MDA-MB-231 cells at 5 uM incubated for 16 hrs by luciferase reporter gene assay | 25190466 |
| HL60 cells | Proliferation assay | 30 μM | 48 h | Antiproliferative activity against human HL60 cells at 30 uM after 48 hrs by MTS assay | 18258440 |
| mouse RAW264.7 cells | Function assay | 2 h | Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method, IC50=0.21 μM | 25176187 | |
| human MV4-11 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay, GI50=1.76 μM | 23411073 | |
| HEK293 cells | Function assay | 24 h | Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay, EC50=2.3 μM | 24955889 | |
| human U2OS cells | Function assay | 5 h | Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay, EC50=3.2 μM | 24900447 | |
| rat H9c2 cells | Function assay | 24 h | Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay, EC50=5.53 μM | 20932762 | |
| human HT-29 cells | Function assay | 10 mins | Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay, EC50=7.24 μM | 24900447 | |
| human RS4:11 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay, GI50=7.25 μM | 23411073 | |
| NCI-H460 cells | Function assay | 2-20 h | Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C, IC50=8.9 μM | 21275386 | |
| human H9 cells | Function assay | 3 days | Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay, EC50=10 μM | 8158164 | |
| mouse B16-4A5 cells | Function assay | 72 h | Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs, IC50=14 μM | 20189399 | |
| K562 cells | Growth inhibition assay | 5 days | Growth inhibition of K562 cells by XTT assay after 5 days, IC50=14.65 μM | 17411092 | |
| human H9 cells | Cytotoxicity assay | 3 days | Cytotoxicity against human H9 cells after 3 days, IC50=16 μM | 8158164 | |
| human HT-29 cells | Function assay | 10 mins | Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins, IC50=18.6 μM | 24900447 | |
| human U937 cells | Proliferation assay | 72 h | Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay, IC50=20 μM | 17158054 | |
| mouse HT22 cells | Function assay | 3 h | Neuroprotective activity in mouse HT22 cells assessed as t-BOOH-induced toxicity at 40 uM preincubated for 3 hrs followed by t-BOOH induction measured after 9 hrs by MTT assay | 24245939 | |
| HEK293 FS cells | Function assay | Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay, IC50=0.85 μM | 20731357 | ||
| CHO cells | Function assay | Agonist activity at rat DAT expressed in CHO cells, EC50=1.45 μM | 20971650 | ||
| RBL-2H3 cells | Function assay | Inhibitory activity against IL-4 production in RBL-2H3 cells was determined, IC50=3.7 μM | 12951092 | ||
| human mast cells | Function assay | Inhibition of SYK in human mast cells assessed as reduction in mast cell degranulation, EC50=4.5 μM | 22257213 | ||
| human LNCAP cells | Function assay | Downregulation of prostate specific antigen secretion in human LNCAP cells, IC50=5 μM | 25019478 | ||
| MDCK cells | Cytotoxicity assay | Cytotoxicity against MDCK cells by MTT assay, CC50=12.44 μM | 18640042 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Luteolin (Luteoline, Luteolol, Digitoflavone)是一种非选择性的PDE抑制剂，作用于PDE1-5，Ki分别为15.0 μM， 6.4 μM， 13.9 μM， 11.1 μM和9.5 μM。 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | Luteolin是在诃子中发现的黄酮类化合物，是非选择性的磷酸二酯酶PDE抑制剂，对PDE1-5的Ki值分别为15.0 μM，6.4 μM，13.9 μM，11.1 μM以及9.5 μM。[1] Luteolin抑制LPS刺激的TNF-α的产生，IC50值低于1 μM。Luteolin抑制LPS诱导的Akt和IkappaBalpha的磷酸化。[2] |
|||
|---|---|---|---|---|
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | FADD / PARP / Cleaved PARP Caspase-3 / Cleaved Caspase-3 / Caspase-8 / Cleaved Caspase-8 ERK / p-ERK / JNK / p-JNK / p38 / p-p38 / Bax / Bcl-2 p-VEGFR2 / p-mTOR / pS6K1 / p70S6K1 / pAKT / AKT / MMP-2 / MMP-9 p21 / Survivin / Cyclin D1 DNMT1 / DMNT3A / DNMT3B TET1 / TET2 / TET3 |
|
30992674 | |
| Immunofluorescence | 5-hmC |
|
30988303 | |
| Growth inhibition assay | Cell viability |
|
30992674 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 | LD50:小鼠>2500毫克/千克(i.g.) [3] |
|
|---|---|---|
化学信息&溶解度
| 分子量 | 286.24 | 分子式 | C15H10O6 |
| CAS号 | 491-70-3 | SDF | Download Luteolin SDF |
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 57 mg/mL ( (199.13 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Ethanol : 20 mg/mL (69.87 mM) Water : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
常见问题及建议解决方法
问题 1:
Would you please suggest a suitable vehicle to dissolve Luteolin for in vivo i.p. use?
回答：
Formula: 5% DMSO+40% PEG 300+5% Tween80+ddH2O, working Solution concentration: up to 7.5mg/ml, stable for 30min.
Tags: buy Luteolin | Luteolin supplier | purchase Luteolin | Luteolin cost | Luteolin manufacturer | order Luteolin | Luteolin distributor
